TY - JOUR
T1 - Soluble CD95 in the serum of patients with low and intermediate grade malignant lymphomas
T2 - Absence of prognostic correlations
AU - Munker, Reinhold
AU - Younes, Anas
AU - Cabanillas, Fernando
AU - Andreeff, Michael
N1 - Copyright:
Copyright 2018 Elsevier B.V., All rights reserved.
PY - 1997
Y1 - 1997
N2 - Several cytokines and the receptors for some cytokines are involved in the pathogenesis and progression of malignant lymphomas. CD95 (Fas/Apo-1) belongs to the TNF-receptor super-family and may mediate apoptosis if triggered by Fas-ligand or specific antibodies. Recently soluble CD95 (a splice variant of the surface-bound molecule) was detected in the serum of patients with lymphoid leukemias and other disorders. In this study, we examined the levels of soluble CD95 (SCD95) in a series of patients with untreated malignant lymphomas and attempted to correlate this molecule with clinical, histological and laboratory parameters. The level of SCD95 was determined in the serum of 66 untreated patients with low and intermediate, grade malignant lymphomas (NHLs) and in 20 normal controls using a solid phase ELISA. The total group of patients with NHLs had a trend towards increased values of SCD95 compared with normal controls (48.8 ± 50.0 versus 75.0 ± 136.3 U/ml, p < 0.1). However, among patients with NHL, elevated SCD95 did not correlate with the presence of B-symptoms, clinical stage, histologic subtype, LDH, β-2 microglobulin, response to therapy or duration of response. We conclude that within the confines of this study, SCD95 has no prognostic value in patients with NHL.
AB - Several cytokines and the receptors for some cytokines are involved in the pathogenesis and progression of malignant lymphomas. CD95 (Fas/Apo-1) belongs to the TNF-receptor super-family and may mediate apoptosis if triggered by Fas-ligand or specific antibodies. Recently soluble CD95 (a splice variant of the surface-bound molecule) was detected in the serum of patients with lymphoid leukemias and other disorders. In this study, we examined the levels of soluble CD95 (SCD95) in a series of patients with untreated malignant lymphomas and attempted to correlate this molecule with clinical, histological and laboratory parameters. The level of SCD95 was determined in the serum of 66 untreated patients with low and intermediate, grade malignant lymphomas (NHLs) and in 20 normal controls using a solid phase ELISA. The total group of patients with NHLs had a trend towards increased values of SCD95 compared with normal controls (48.8 ± 50.0 versus 75.0 ± 136.3 U/ml, p < 0.1). However, among patients with NHL, elevated SCD95 did not correlate with the presence of B-symptoms, clinical stage, histologic subtype, LDH, β-2 microglobulin, response to therapy or duration of response. We conclude that within the confines of this study, SCD95 has no prognostic value in patients with NHL.
KW - Intermediate and low-grade lymphomas
KW - Prognosis
KW - Soluble CD95
UR - http://www.scopus.com/inward/record.url?scp=0031461049&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0031461049&partnerID=8YFLogxK
U2 - 10.3109/10428199709058319
DO - 10.3109/10428199709058319
M3 - Article
C2 - 9477134
AN - SCOPUS:0031461049
SN - 1042-8194
VL - 27
SP - 517
EP - 521
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 5-6
ER -